Interestingly, our meta-analysis suggested significant decrease in FOXP3 protein levels in blood (p < 0.00001, SMD: -4.94 [-6.96, -2.91]), Figure 3(b)) and skin (p = 0.002, SMD: -7.16 [-11.73, -2.59]), Figure 3(b)) of vitiligo patients when compared to controls. The gene discussed is FOXP3; the disease is vitiligo.